FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 11, 2016--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee
for Medicinal Products for Human Use (CHMP), the scientific committee of
the European Medicines Agency (EMA), has adopted a positive opinion on
the company’s Marketing Authorization Application (MAA) for Vemlidy®
(tenofovir alafenamide, TAF) 25 mg, an investigational, once-daily
tablet for the treatment of chronic hepatitis B virus (HBV) infection in
adults and adolescents (≥ 12 years and ≥ 35 kg body weight). The data
included in the application support the use of TAF in treatment-naïve
and treatment-experienced adults and adolescents with HBeAg-negative and
HBeAg-positive HBV infection.

TAF is a novel, targeted prodrug of tenofovir that has demonstrated
antiviral efficacy similar to and at one-tenth the dose of Gilead’s
Viread® (tenofovir disoproxil fumarate, TDF) 245 mg. Data
show that because TAF has greater plasma stability and more efficiently
delivers tenofovir to hepatocytes compared to TDF, it can be given at a
lower dose, resulting in less tenofovir in the bloodstream. As a result,
TAF improved certain renal and bone laboratory safety parameters
compared to TDF in clinical trials.

The CHMP’s recommendation will now be reviewed by the European
Commission, which has the authority to approve medicines for use in the
28 countries of the European Union, Norway and Iceland.

The MAA for TAF includes data from two international Phase 3 studies
(Studies 108 and 110) in 1,298 treatment-naïve and treatment-experienced
patients with HBV infection. Study 108 randomized 425 HBeAg-negative
patients to receive either TAF or TDF, and Study 110 randomized 873
HBeAg-positive patients to receive either TAF or TDF. The full data from
Studies 108 and 110 were presented at the International Liver Congress™
(ILC) earlier this year.

TAF as a single-agent for HBV is an investigational product and its
safety and efficacy have not yet been established.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Gilead has operations in more
than 30 countries worldwide, with headquarters in Foster City,
California.

Forward-Looking Statement

This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including the
risk that the European Commission or other regulatory agencies may not
approve TAF for the treatment of chronic hepatitis B and that any
marketing approvals, if granted, may have significant limitations on its
use. As a result, Gilead may not be able to successfully commercialize
TAF for chronic hepatitis B. These risks, uncertainties and other
factors could cause actual results to differ materially from those
referred to in the forward-looking statements. The reader is cautioned
not to rely on these forward-looking statements. These and other risks
are described in detail in Gilead’s Quarterly Report on Form 10-Q for
the quarter ended September 30, 2016, as filed with the U.S. Securities
and Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.

Viread

Please refer to the Viread individual Summary of Product
Characteristics for full prescribing information.

Any suspected adverse reactions to Viread should be reported to
Gilead via email to safety_FC@gilead.com
or by telephone +44 (0) 1223 897500.